Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926975 · ClinicalTrials.gov registry record · NA
The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width
A NA study of Ocular Hypertension, sponsored by University of Houston.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT03926975: Completed NA study of Ocular Hypertension, sponsored by University of Houston.
NCT03926975 is a NA study of Ocular Hypertension that has completed, run by University of Houston. The registered enrollment target is 26 participants, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926975, a NA study of Ocular Hypertension, has completed, sponsored by University of Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the use of two instruments to measure changes in two ocular structures: 1) the anterior chamber depth (ACD) - measured using low coherence optical biometry, and 2) minimum rim width of the optic nerve head (MRW) - measured using optical coherence tomography. Changes in these ocular structures indicate fluctuations in intraocular pressure (IOP) and will be measured during scleral contact lens (SGP) wear to determine if SGP wear influences IOP. We hypothesize that a scleral lens increases the intraocular pressure (IOP) during active wear and that the ACD and MRW will also change.
Primary Outcome
The Bruch's membrane opening to the inner limiting lamina (termed the minimum rim width) will be measured at the optic nerve head.
Conditions Studied
Interventions
- DEVICE Scleral Lens
- OTHER No lens
Study Locations (1)
Texas
- University Eye Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2019-08-30 |
| Phase | NA |
What the finished NCT03926975 record still lists
NCT03926975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Scleral Lens is the first listed.
NCT03926975 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03926975 about?
NCT03926975 is a clinical study titled "The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width". The purpose of this study is to evaluate the use of two instruments to measure changes in two ocular structures: 1) the anterior chamber depth (ACD) - measured using low coherence optical biometry, and 2) minimum rim width of the optic nerve head (MRW) - measured using optical coherence tomography. ...
What is the current status of trial NCT03926975?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2018-06-01. Estimated completion is 2019-08-30.
What conditions does trial NCT03926975 study?
This clinical trial studies the following conditions: Ocular Hypertension.
What interventions are being tested in trial NCT03926975?
The interventions under investigation include: Scleral Lens (DEVICE), No lens (OTHER).
Who is sponsoring clinical trial NCT03926975?
This trial is sponsored by University of Houston, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03926975 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03926975's enrollment target sits among peer trials
26 52nd of 54 higher than 3 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
RECRUITING · NA
-
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
RECRUITING · NA
-
Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects
COMPLETED · NA
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI